MDLN

Medline Inc.

Fundamental data last updated:September 4, 2026

We may earn a commission from partner links. This content is for informational purposes only and is not financial advice. Information may be delayed or inaccurate.

company profile

SECTOR

Healthcare

industry

Medical - Instruments & Supplies

Exchange

NASDAQ

County of HQ

US

Next Earnings Date

Pending Announcement

Business Summary

Medline Inc. manufactures med-surg products serving the hospital, surgery centers, physician offices, post-acute facilities, and nursing home sites of care in the United States and Internationally. It operates through two segments: Medline Brand and Supply Chain Solutions. The Medline Brand segment procures and manufactures products from three product categories include surgical solutions, front line care, and laboratory and diagnostics. Its front line care offers med-surg products for patient-facing needs, including wound care products, exam gloves, skin care and incontinence products, environment cleaning supplies, textiles, hand sanitizer, durable medical equipment, patient plastics, and decolonization and infection control products. Its surgical solutions provide operating room and perioperative environment product solutions, including surgical procedure trays, drapes and gowns, personal protective equipment, sterile wraps, surgical instruments, surgeon's gloves, procedure kits, and orthopedic implants. Its laboratory and diagnostics offer laboratory and diagnostic product solutions, including point of care testing, analyzers and instrumentation, lab and diagnostic consumables, diagnostic instruments, vital signs monitors, and anatomic pathology and phlebotomy products. It provides its products to domestic and international consumers. The Supply Chain Solutions segment procures and distributes a variety of third-party products from national brands. It provides logistics and supply chain optimization services to domestic and international consumers. It also provides supply chain optimization services such as, consulting engagements, outsourced warehouse and technology management, put-away-ready packaging, third-party logistics, inventory rationalization, and route planning. Medline Inc. was founded in 1966 and is based in Northfield, Illinois.

 


VALUATION

P/E

31.79

Market Cap ($M USD)

$31.64B

Forward P/E

15.74

PEG

0.15

PRICE TO SALES

1.09

PRICE TO BOOK

2.72

EV / EBITDA

14.25

5-Year Average P/E

Free Cash Flow Yield

4.82%

DCF Value

$114.87

Graham Number

$19.09

Price to FCF

20.75

EV to FCF

27.53

Earnings Yield

3.15%

FCF Yield

4.82%

DIVIDEND

Yield

0.00%

Annual Payout

$0.00

Payout Ratio

0.00%

Consecutive Years of Dividend Growth

5-Year Dividend Growth Rate

Financial Health & Profitability

Earnings Per Share

$1.18

Next Year EPS Growth Estimate

$2.38

Next Year Revenue Growth Estimate

$41.30B

Return on Equity (ROE)

6.87%

FREE CASH FLOW

Operating Margin

7.04%

Debt-to-Equity

1.17

Piotroski F-Score

6

Altman Z-Score

2.13

Return on Invested Capital (ROIC)

5.62%

Current Ratio

4.41

Quick Ratio

2.51

Net Debt to EBITDA

3.51

Interest Coverage

3.43

Gross Profit margin

24.04%

FCF PER SHARE

$1.86

REVENUE PER SHARE

$35.58

Gainseekers Quantitative Analysis

Summary

MDLN Medline Inc. appears to be significantly undervalued based on its DCF Value, which towers over the recent pricing. The Forward P/E of 16.63 suggests a more reasonable valuation compared to its current P/E, indicating potential growth. However, the Altman Z-score of 2.17 raises concerns about financial stability, hinting at moderate distress risk. The Earnings Yield of 2.98% is underwhelming, suggesting limited immediate returns. Overall, the market seems to be mispricing this stock, offering a potential opportunity for savvy investors.

AI Exposure / Tech Reliance

Operating in the Medical - Instruments & Supplies industry, MDLN is well-positioned to leverage AI and modern tech advancements. The healthcare sector's increasing reliance on technology for diagnostics and supply chain optimization plays to MDLN's strengths. This adaptability could enhance operational efficiency and product innovation.

The Bull Case

For value or GARP investors, MDLN offers compelling reasons to buy. The ROIC of 5.62% and a Piotroski F-Score of 6 indicate solid capital efficiency and financial health. Despite a modest Operating Margin of 7.04%, the company's FCF Yield of 4.75% suggests strong cash generation capabilities. These metrics reflect a company with pricing power and the ability to reinvest effectively in growth opportunities.

The Bear Case

Despite some strengths, MDLN faces structural risks. The Price/Book ratio of 2.87 and Price/Sales of 1.10 suggest the stock might be overvalued relative to its book and sales values. Additionally, the Net Debt to EBITDA ratio of 3.51 indicates significant leverage, which could be problematic if earnings falter. The stock's distance from its 52-week high suggests potential technical overextension, raising caution for momentum investors.

Market Sentiment & Smart Money

Short Interest %

Analyst Consensus

Buy

Average Analyst Price Target

$48.91

Institutional Ownership %

1-Year Beta

0.18

Insider Buying % (6 Mo)

Distance to 52-Week High

35.96%

Distance to 52-Week Low

6.76%

EARNINGS SURPRISE %

11.79%

50-DAY SMA

$42.56

200-DAY SMA

$43.40

⚠️ Financial Disclaimer:
This content is for informational purposes only and is not financial advice. Information may be delayed or inaccurate. We may earn a commission from partner links.